Health Canada approves Rexulti (brexpiprazole) for agitation associated with Alzheimer’s disease-related dementia
Health Canada has approved Rexulti (brexpiprazole) for agitation associated with Alzheimer’s disease-related dementia in patients with aggressive behavior
The treatment, co-developed by Otsuka Pharmaceuticals and Lundbeck, was recently approved by the FDA for the same indication.
“Today marks a major milestone for patients, caregivers, and families navigating the complexities of agitation associated with dementia due to Alzheimer’s disease,” according to Michael Laranjo, president and general manager of Otsuka Canada,
Rexulti’s recommended starting dose is 0.5 mg taken once daily for one week, followed by 1 mg once daily for another week, and 2 mg once daily thereafter. The dosing may be increased up to a maximum daily dose of 3 mg after at least two weeks, based on a patient’s clinical response and tolerability.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins